Despite the end of federal shortages of popular GLP-1 weight-loss medications, the market for compounded alternatives remains strong—and some patients may unknowingly be receiving products from pharmacies with concerning regulatory histories, according to new research from the University of Colorado Anschutz.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗